Skip to main content

29.02.2024 | Case Report

Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature

verfasst von: Shota Mochizuki, Junnosuke Miura, Kiwako Ucida, Ryo Kubota, Hirona Fujikawa, Satoshi Takagi, Naoshi Yoshida, Sachiko Ootake, Chika Fujimori, Akihito Shinohara, Junji Tanaka, Tetsuya Babazono

Erschienen in: Diabetology International

Einloggen, um Zugang zu erhalten

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection, which led to the coronavirus 2019 (COVID-19) pandemic, has promoted the development of novel therapeutic agents and vaccines to combat the global spread of the virus. While the COVID-19 vaccines approved thus far have proven to be effective in clinical settings, there have been reports of autoimmune diseases occurring following vaccination, including autoimmune/inflammatory syndrome induced by adjuvant syndrome. We herein report two cases of type 1 diabetes mellitus that occurred following COVID-19 vaccination and provide a literature review. Both cases received multiple vaccinations as recommended to ensure optimal antibody titers. Moreover, the HLA associated with susceptibility to type 1 diabetes was prototypic in both cases. This indirect evidence suggests that the COVID-19 vaccines may be implicated in the pathogenesis of type 1 diabetes. Further case reports to establish a clearer understanding of a potential association are warranted.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9:467.PubMedCrossRef Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9:467.PubMedCrossRef
3.
Zurück zum Zitat Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021;31:1436–9.PubMedCrossRef Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021;31:1436–9.PubMedCrossRef
5.
Zurück zum Zitat Das L, Bhadada SK, Sood A. Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J Endocrinol Invest. 2022;45:465–7.PubMedCrossRef Das L, Bhadada SK, Sood A. Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J Endocrinol Invest. 2022;45:465–7.PubMedCrossRef
6.
Zurück zum Zitat Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12: 714170.PubMedPubMedCentralCrossRef Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12: 714170.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–16.PubMedPubMedCentralCrossRef Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–16.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Rosenberg ES, Dorabawila V, Easton D, et al. COVID-19 vaccine effectiveness by product and timing in New York State 2021. N Engl J Med. 2022;386:116–27.PubMedCrossRef Rosenberg ES, Dorabawila V, Easton D, et al. COVID-19 vaccine effectiveness by product and timing in New York State 2021. N Engl J Med. 2022;386:116–27.PubMedCrossRef
9.
Zurück zum Zitat Pomara C, Sessa F, Ciaccio M, Dieli F, Esposito M, et al. COVID-19 vaccine and death: causality algorithm according to the WHO Eligibility Diagnosis. Diagnostics (Basel). 2021;11:955.PubMedCrossRef Pomara C, Sessa F, Ciaccio M, Dieli F, Esposito M, et al. COVID-19 vaccine and death: causality algorithm according to the WHO Eligibility Diagnosis. Diagnostics (Basel). 2021;11:955.PubMedCrossRef
10.
Zurück zum Zitat Wang L, Wang FS, Gershwin ME, Gershwin E. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95.PubMedCrossRef Wang L, Wang FS, Gershwin ME, Gershwin E. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95.PubMedCrossRef
11.
Zurück zum Zitat Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13:736–41.PubMedCrossRef Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13:736–41.PubMedCrossRef
12.
13.
Zurück zum Zitat Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;15(362):1659–66.CrossRef Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;15(362):1659–66.CrossRef
14.
Zurück zum Zitat Ruggeri RM, Giovanellla L, Campennì A. SARS-CoV-2 vaccine may trigger thyroid autoimmunity: real-life experience and review of the literature. J Endocrinol Invest. 2022;45:2283–9.PubMedPubMedCentralCrossRef Ruggeri RM, Giovanellla L, Campennì A. SARS-CoV-2 vaccine may trigger thyroid autoimmunity: real-life experience and review of the literature. J Endocrinol Invest. 2022;45:2283–9.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44:1085–90.PubMedCrossRef Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44:1085–90.PubMedCrossRef
16.
Zurück zum Zitat Sakurai K, Narita D, Saito N, Ueno T, Sato R, et al. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. J Diabetes Investig. 2022;13:1290–2.PubMedPubMedCentralCrossRef Sakurai K, Narita D, Saito N, Ueno T, Sato R, et al. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. J Diabetes Investig. 2022;13:1290–2.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084–92.PubMedCrossRef Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084–92.PubMedCrossRef
18.
Zurück zum Zitat Abdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7:101–7.PubMedCrossRef Abdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7:101–7.PubMedCrossRef
22.
Zurück zum Zitat Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130: 110542.PubMedCrossRef Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130: 110542.PubMedCrossRef
23.
Zurück zum Zitat Samuel I, Hubert M. Innate viral sensor MDA5 and coxsackievirus interplay in type 1 diabetes development. Microorganisms. 2020;8:993.CrossRef Samuel I, Hubert M. Innate viral sensor MDA5 and coxsackievirus interplay in type 1 diabetes development. Microorganisms. 2020;8:993.CrossRef
24.
Zurück zum Zitat Sasaki K, Morioka T, Okada N, Natsuki Y, Kakutani Y, Ochi A, et al. New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. J Diabetes Invest. 2022;13:1286–9.CrossRef Sasaki K, Morioka T, Okada N, Natsuki Y, Kakutani Y, Ochi A, et al. New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. J Diabetes Invest. 2022;13:1286–9.CrossRef
25.
Zurück zum Zitat Yano M, Morioka T, Natsuki Y, Sasaki K, Kakutani Y, Ochi A, et al. New-onset type 1 diabetes after COVID-19 mRNA vaccination. Intern Med. 2022;61:1197–200.PubMedPubMedCentralCrossRef Yano M, Morioka T, Natsuki Y, Sasaki K, Kakutani Y, Ochi A, et al. New-onset type 1 diabetes after COVID-19 mRNA vaccination. Intern Med. 2022;61:1197–200.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Sasaki H, Itoh A, Watanabe Y, Nakajima Y, Saisho Y, Irie J, et al. Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report. J Diabetes Invest. 2022;13:1105–8.CrossRef Sasaki H, Itoh A, Watanabe Y, Nakajima Y, Saisho Y, Irie J, et al. Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report. J Diabetes Invest. 2022;13:1105–8.CrossRef
27.
Zurück zum Zitat Sato T, Kodama S, Kaneko K, Imai J, Katagiri H. Type 1 diabetes mellitus associated with nivolumab after second SARS-CoV-2 vaccination. Jpn Emerg Infect Dis. 2022;28:1518–20.CrossRef Sato T, Kodama S, Kaneko K, Imai J, Katagiri H. Type 1 diabetes mellitus associated with nivolumab after second SARS-CoV-2 vaccination. Jpn Emerg Infect Dis. 2022;28:1518–20.CrossRef
29.
Zurück zum Zitat Bleve E, Venditti V, Lenzi A, Morano S, Filardi T. COVID-19 vaccine and autoimmune diabetes in adults: report of two cases. J Endocrinol Invest. 2022;45:1269–70.PubMedPubMedCentralCrossRef Bleve E, Venditti V, Lenzi A, Morano S, Filardi T. COVID-19 vaccine and autoimmune diabetes in adults: report of two cases. J Endocrinol Invest. 2022;45:1269–70.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021;125: 102738.PubMedPubMedCentralCrossRef Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021;125: 102738.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Ohuchi K, Amagai R, Tamabuchi E, Kambayashi Y, Fujimura T. Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. J Dermatol. 2022;49:e167–8.PubMedCrossRef Ohuchi K, Amagai R, Tamabuchi E, Kambayashi Y, Fujimura T. Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. J Dermatol. 2022;49:e167–8.PubMedCrossRef
33.
Zurück zum Zitat Moon H, Suh S, Park MK. Adult-onset type 1 diabetes development following COVID-19 mRNA vaccination. J Korean Med Sci. 2023;38: e12.PubMedCrossRef Moon H, Suh S, Park MK. Adult-onset type 1 diabetes development following COVID-19 mRNA vaccination. J Korean Med Sci. 2023;38: e12.PubMedCrossRef
34.
Zurück zum Zitat Tanaka S, Endo T, Aida K, Shimura H, Yokomori N, Kaneshige M, et al. Distinct diagnostic criteria of fulminant type 1 diabetes based on serum C-peptide response and HbA1c levels at onset. Diabetes Care. 2004;27:1936–41.PubMedCrossRef Tanaka S, Endo T, Aida K, Shimura H, Yokomori N, Kaneshige M, et al. Distinct diagnostic criteria of fulminant type 1 diabetes based on serum C-peptide response and HbA1c levels at onset. Diabetes Care. 2004;27:1936–41.PubMedCrossRef
35.
Zurück zum Zitat Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne). 2017;8:343.PubMedCrossRef Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne). 2017;8:343.PubMedCrossRef
36.
Zurück zum Zitat Nemoto M, Sugisawa H, Nishimura R, et al. Factors affecting the honeymoon period in adult-onset Japanese type 1 diabetes. J Jpn Diab Soc. 2011;54:98–102. Nemoto M, Sugisawa H, Nishimura R, et al. Factors affecting the honeymoon period in adult-onset Japanese type 1 diabetes. J Jpn Diab Soc. 2011;54:98–102.
37.
Zurück zum Zitat Chang L, Mo-Ning G, Zhonglin C, Zhong X, Guanjie C. Association between Covid-19 vaccination and incidence of type 1 diabetes in China: evidence from 14.14 million registered residents between 2007 and 2021. Diabetes Res Clin Pract. 2023;201:110723.CrossRef Chang L, Mo-Ning G, Zhonglin C, Zhong X, Guanjie C. Association between Covid-19 vaccination and incidence of type 1 diabetes in China: evidence from 14.14 million registered residents between 2007 and 2021. Diabetes Res Clin Pract. 2023;201:110723.CrossRef
38.
Zurück zum Zitat Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef
39.
Zurück zum Zitat Imagawa A, Hanafusa T. Fulminant type 1 diabetes—east and west. J Clin Endocrinol Metab. 2023;108:e1473–8.PubMedCrossRef Imagawa A, Hanafusa T. Fulminant type 1 diabetes—east and west. J Clin Endocrinol Metab. 2023;108:e1473–8.PubMedCrossRef
40.
Zurück zum Zitat Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Invest. 2012;3:62–9.CrossRef Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Invest. 2012;3:62–9.CrossRef
41.
Zurück zum Zitat Ikegami H, Ogihara T. Genetics of insulin-dependent diabetes mellitus. Endocr J. 1996;43:605–13.PubMedCrossRef Ikegami H, Ogihara T. Genetics of insulin-dependent diabetes mellitus. Endocr J. 1996;43:605–13.PubMedCrossRef
Metadaten
Titel
Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature
verfasst von
Shota Mochizuki
Junnosuke Miura
Kiwako Ucida
Ryo Kubota
Hirona Fujikawa
Satoshi Takagi
Naoshi Yoshida
Sachiko Ootake
Chika Fujimori
Akihito Shinohara
Junji Tanaka
Tetsuya Babazono
Publikationsdatum
29.02.2024
Verlag
Springer Nature Singapore
Erschienen in
Diabetology International
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00695-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.